GHRP-6.
GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2.
GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. GHRP-6 is research / preclinical, and PepCue grades its published evidence D tier (38/100). This is a research reference, not medical or dosing advice.
What it is
GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. First described by endocrinologist Cyril Y. Bowers and colleagues in the mid-1980s, it was the prototype of the growth hormone secretagogue (GHS) class and the chemical ancestor of later peptides such as GHRP-2, hexarelin, and ipamorelin. It is not a hormone replacement; rather, it provokes the body's own pituitary to release growth hormone.
How it works
GHRP-6 is a synthetic agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the G-protein-coupled receptor cloned in 1996 whose endogenous ligand, ghrelin, was identified in 1999. Receptor activation drives phospholipase C signaling, raising inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium and activating protein kinase C, which triggers GH release from somatotrophs. This pathway is distinct from and synergistic with GHRH (which signals through cAMP/PKA), and GHRP-6 also acts on the hypothalamus to amplify GHRH tone and suppress somatostatin. Separately, GHRP-6 binds the scavenger receptor CD36, which is implicated in its proposed cytoprotective and anti-ischemic effects independent of GH release. It also stimulates appetite (via NPY/AgRP arcuate neurons) and can transiently raise cortisol and prolactin.
Mechanism pathways
Acting on the ghrelin / GH-secretagogue receptor, a pathway separate from GHRH.
The growth hormone secretagogue receptor, GHS-R1a, is a G-protein-coupled receptor expressed on pituitary somatotrophs and in hypothalamic nuclei. Its natural ligand is ghrelin, the stomach-derived hormone associated with hunger. Activation raises growth hormone through a route entirely separate from GHRH: it acts directly on somatotrophs, and it also suppresses hypothalamic somatostatin tone, effectively releasing the brake at the same time as pressing the accelerator. This dual action is why compounds at this receptor and GHRH analogs are often studied together, since combining them produces a larger growth hormone response than either produces alone. The history here is unusual. The synthetic peptides in this group were developed in the 1980s and 1990s by working backwards from observed growth hormone release, years before ghrelin itself was identified in 1999. They were the pharmacological tools that led researchers to the receptor. They are therefore best understood as synthetic ghrelin mimetics that happened to be discovered before the hormone they mimic. Members of this group differ chiefly in selectivity, which is the practical distinction that matters most. GHS-R1a activation is not confined to growth hormone. Because the receptor sits on cells that also govern prolactin and adrenocorticotropic hormone release, and because ghrelin signalling drives appetite and influences gastric motility, several of these compounds raise cortisol and prolactin and increase hunger alongside the intended growth hormone effect. Others were specifically designed to avoid that, producing a comparatively clean growth hormone response with minimal spillover onto the other axes. Some also show additional activity at the CD36 receptor, which has been studied in cardiac contexts. Honest assessment of clinical relevance: the acute receptor pharmacology is well characterised, including in short human studies where growth hormone reliably rises after administration. That is proof of mechanism. What does not exist for this class is proof of benefit. No compound in this group is an approved medicine, controlled trials of sustained use with body composition or clinical endpoints are essentially absent, and material sold under these names is unregulated research-grade product of uncertain content. Growth hormone secretagogues are also prohibited in sport by anti-doping authorities. A further consideration specific to this receptor is desensitisation: sustained agonism at a G-protein-coupled receptor commonly reduces its responsiveness over time, so the acute hormonal response observed in a short study is not a reliable guide to what happens with continued use.
The evidence
In humans, the best-established data are pharmacological/diagnostic: GHRP-6 reliably and synergistically stimulates GH secretion (especially combined with GHRH) and was studied as a GH-provocative agent and probe of the somatotropic axis in the 1990s. Beyond GH provocation, the much-publicized cytoprotective, cardioprotective, and wound/scar-reducing claims rest almost entirely on preclinical work: rodent myocardial infarction and reperfusion models, a rat/rabbit wound and hypertrophic-scar study (Plastic Surgery International, 2016, animal-only), and doxorubicin-cardiotoxicity models. A Clinical Science (2006) paper proposed GHRP-6 for prevention of multiple organ failure, but this remained largely conceptual/preclinical. There are no large, completed, peer-reviewed randomized human trials demonstrating clinical benefit for cardioprotection, healing, or body composition; the human-versus-animal gap here is wide and should not be glossed over.
The evidence, in brief
A synthetic GH-releasing peptide / ghrelin-receptor agonist. Human data come largely from small pharmacokinetic and GH-stimulation studies; broader cytoprotective claims rest mostly on preclinical work. No large human outcome trials, not FDA-approved.
- García-Fernández R et al.: Pharmacokinetic study of GHRP-6 in nine healthy male volunteersEur J Pharm Sci, 2013 (PMID 23099431)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #024
Mostly preclinical or mechanistic; little human data.
Some early human evidence exists but isn't definitive.
Claim receipts
Popular claims about GHRP-6, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Reliable GH stimulation is documented in human provocation studies, especially in combination with GHRH.
Cardioprotection findings come from rodent infarction, reperfusion and cardiotoxicity models.
Wound and hypertrophic-scar work is animal-only; no completed human trial supports it.
The proposal remained largely conceptual and preclinical and was never tested as a human outcome.
Marked appetite stimulation is documented in humans alongside transient cortisol and prolactin rises.
Safety profile
Documented effects in human GH-testing studies include marked stimulation of appetite and transient, usually modest, increases in cortisol and prolactin alongside the intended GH rise, reflecting limited receptor selectivity compared with newer agents like ipamorelin. Because GHS-R1a agonism raises GH and downstream IGF-1, theoretical concerns include fluid retention, insulin resistance/altered glucose handling, and the general caution that sustained GH/IGF-1 elevation could promote growth of existing tumors; these long-term risks are not well characterized for GHRP-6 specifically. There are no robust long-term human safety data, no established safety in pregnancy, and product purity/identity is a major real-world hazard since material sold for "research" is unregulated. No dosing or administration guidance is provided here.
Compound notes
- GHRP-6 is a synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, first described by Cyril Bowers and colleagues in the mid-1980s as the prototype of the growth hormone secretagogue class.
- It is an agonist at GHS-R1a, the receptor cloned in 1996 before its endogenous ligand ghrelin was identified in 1999. Studying peptides like GHRP-6 is what led researchers to that receptor and hormone.
- It acts synergistically with GHRH, which signals through a separate cAMP/PKA pathway, and also works on the hypothalamus to amplify GHRH tone and suppress somatostatin.
- Separately it binds the scavenger receptor CD36, the basis for its proposed cytoprotective and anti-ischemic effects independent of GH release.
GHRP-6 is the least selective of the family: it stimulates appetite strongly and can raise cortisol and prolactin. GHRP-2 does so to a lesser degree, and ipamorelin was designed to minimize both.
- Not FDA-approved for any therapeutic indication; research-use-only and prohibited at all times in sport by WADA.
- Human effects documented in GH-testing studies include marked appetite stimulation and transient rises in cortisol and prolactin alongside the intended GH rise.
- Cardioprotective, wound-healing and organ-failure-prevention claims rest on animal models rather than completed human trials, and robust long-term human safety data does not exist.
Regulatory status
GHRP-6 is not approved by the FDA (or other major regulators) for any therapeutic indication and is an investigational/research-use-only compound. As a growth hormone secretagogue, it falls under substances prohibited in sport at all times by the World Anti-Doping Agency (WADA).
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Hexapeptide sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; the first-described synthetic growth hormone secretagogue (Bowers, mid-1980s)
- 02Acts as an agonist at GHS-R1a, the ghrelin receptor cloned in 1996 before ghrelin itself was identified in 1999
- 03Studying these synthetic peptides historically helped lead researchers to discover the ghrelin receptor and ghrelin
- 04Less receptor-selective than later peptides; stimulates appetite and can raise cortisol and prolactin in addition to GH
- 05Also binds the CD36 scavenger receptor, the basis for its proposed (preclinical) cytoprotective effects
- 06Cardioprotective, wound-healing, and organ-failure-prevention claims are supported by animal models, not completed human trials
GHRP-6: research formats
Choose the format you are researching to see route-specific notes.
Older ghrelin mimetic; stronger appetite drive than GHRP-2 at the same dose.
GHRP-6 has essentially the same injection format as GHRP-2: 5 mg vials reconstituted with 2.0 mL BAC water for 2,500 mcg/mL. The key practical difference is that GHRP-6 produces a notably stronger appetite stimulus than GHRP-2 at comparable doses.
Sources
Every factual claim above resolves to a real, published source.
- Growth hormone-releasing peptide (GHRP)Cell Mol Life Sci, 1998, PMID 9893708
- On a peptidomimetic growth hormone-releasing peptideJ Clin Endocrinol Metab, 1994, PMID 7962301
- Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failureClin Sci (Lond), 2006, PMID 16417467
- Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds (animal study)Plastic Surgery International, 2016, PMID 27200188
Cite this page
PepCue. “GHRP-6: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/ghrp-6.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.